enGene announces name change to enGene Therapeutics

enGene (ENGN) will change its corporate name to “enGene Therapeutics Inc.” effective April 8. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene’s ongoing LEGEND trial is investigating detalimogene across several cohorts of high-risk non-muscle invasive bladder cancer, including a pivotal cohort in BCG-unresponsive NMIBC with carcinoma in situ. The Company’s common shares will continue to trade on the Nasdaq Capital Market under the symbol “ENGN”, and the Company’s listed common share purchase warrants will continue to trade on the Nasdaq under the symbol “ENGNW”. The corporate name change does not affect the rights of security holders, and no further action is required by security holders with respect to the change. As of the effective date, the CUSIP numbers and ISINs of the Common Shares and Warrants will change. The new CUSIP number for the Common Shares is 29286X101 and the new ISIN number is CA29286X1015. The new CUSIP number for the Warrants is 29286X119 and the new ISIN number is CA29286X1197.